BRPI0513186A - medicinal composition for oral administration - Google Patents

medicinal composition for oral administration

Info

Publication number
BRPI0513186A
BRPI0513186A BRPI0513186-3A BRPI0513186A BRPI0513186A BR PI0513186 A BRPI0513186 A BR PI0513186A BR PI0513186 A BRPI0513186 A BR PI0513186A BR PI0513186 A BRPI0513186 A BR PI0513186A
Authority
BR
Brazil
Prior art keywords
oral administration
medicinal composition
composition
loxoprofen
reduced risk
Prior art date
Application number
BRPI0513186-3A
Other languages
Portuguese (pt)
Inventor
Yasuhiro Torizumi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35783918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513186(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0513186A publication Critical patent/BRPI0513186A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSIçãO MEDICINAL PARA A ADMINISTRAçãO ORAL. Uma composição contendo loxoprofeno para a administração oral, que apresenta um risco reduzido em causar distúrbios da mucosa gástrica. A composição para a administração oral compreende loxoprofeno e um agente antiácido.MEDICAL COMPOSITION FOR ORAL ADMINISTRATION. A composition containing loxoprofen for oral administration, which has a reduced risk of causing gastric mucosal disorders. The composition for oral administration comprises loxoprofen and an antacid agent.

BRPI0513186-3A 2004-07-13 2005-07-12 medicinal composition for oral administration BRPI0513186A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004205934 2004-07-13
PCT/JP2005/012798 WO2006006577A1 (en) 2004-07-13 2005-07-12 Loxoprofen-containing composition for oral administration

Publications (1)

Publication Number Publication Date
BRPI0513186A true BRPI0513186A (en) 2008-04-29

Family

ID=35783918

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513186-3A BRPI0513186A (en) 2004-07-13 2005-07-12 medicinal composition for oral administration

Country Status (5)

Country Link
JP (6) JP2012051949A (en)
KR (1) KR20070034576A (en)
CN (1) CN101014333A (en)
BR (1) BRPI0513186A (en)
WO (1) WO2006006577A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008195705A (en) * 2007-01-15 2008-08-28 Daiichi Sankyo Healthcare Co Ltd Loxoprofen-containing oral composition
JP5681430B2 (en) * 2009-09-30 2015-03-11 興和株式会社 Loxoprofen-containing pharmaceutical composition
JP2011132226A (en) * 2009-11-27 2011-07-07 Kowa Co Loxoprofen-containing medicinal composition and medicinal preparation containing the composition
JP6139050B2 (en) * 2010-08-27 2017-05-31 興和株式会社 Medicine
CN105501856B (en) * 2015-12-11 2017-11-17 江苏大学 A kind of powder filled rate detection means of spiral quantitative charger feeding-distribution device and method
CN113631731A (en) 2019-03-13 2021-11-09 杰富意钢铁株式会社 Thick steel plate and method for producing same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704721B2 (en) * 1987-02-12 1998-01-26 ライオン株式会社 Ibuprofen formulation
JP3122748B2 (en) * 1991-11-29 2001-01-09 ライオン株式会社 Antipyretic analgesic containing ibuprofen
JP4113267B2 (en) * 1997-04-03 2008-07-09 日医工株式会社 Loxoprofen sodium-containing tablets
JP4936579B2 (en) * 1997-09-05 2012-05-23 第一三共株式会社 Loxoprofen-containing pharmaceutical preparation
JP2001172175A (en) * 1999-12-14 2001-06-26 Taisho Pharmaceut Co Ltd Composition for the cold
JP2001181190A (en) * 1999-12-22 2001-07-03 Takeda Chem Ind Ltd Medicine composition
JP2001199882A (en) * 2000-01-20 2001-07-24 Taisho Pharmaceut Co Ltd Composition for cold and rhinitis
JP2002226366A (en) * 2001-02-02 2002-08-14 Yuutoku Yakuhin Kogyo Kk Liniment preparation for external use
JP4365107B2 (en) * 2001-05-25 2009-11-18 エスエス製薬株式会社 Pharmaceutical composition
JP4614640B2 (en) * 2002-07-04 2011-01-19 第一三共株式会社 Antipyretic composition
JP2004161667A (en) * 2002-11-13 2004-06-10 Saiseido Yakuhin Kk Crude drug-formulated pharmaceutical composition

Also Published As

Publication number Publication date
WO2006006577A1 (en) 2006-01-19
JP6106727B2 (en) 2017-04-05
JP2014098036A (en) 2014-05-29
KR20070034576A (en) 2007-03-28
JP2016056195A (en) 2016-04-21
JP2014132038A (en) 2014-07-17
JP2012051950A (en) 2012-03-15
JP5833157B2 (en) 2015-12-16
JP6192751B2 (en) 2017-09-06
JP2012051949A (en) 2012-03-15
CN101014333A (en) 2007-08-08
JP2016027058A (en) 2016-02-18

Similar Documents

Publication Publication Date Title
CY1121350T1 (en) ORAL PHARMACEUTICAL FORMS OF CYTIDINE ANALOGS AND METHODS OF USING THEM
AR049985A1 (en) COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES
DE602004019053D1 (en) TITRATION DOCUMENT SCHEME FOR CONTROLLED RELEASED TRAMADOL
AR045972A1 (en) FORMULATIONS OF RELEASE OF SUSTAINED LIBERATION WITH EFFECTIVENESS OF 24 HOURS
MX2009003372A (en) Non-mucoadhesive film dosage forms.
BR9916224A (en) Oral pharmaceutical dosage form, processes for the manufacture of a fixed dosage form, for the treatment and prophylaxis of gastrointestinal disorders and to prevent gastrointestinal side effects, use of a dosage form, combination, and ampoule packaging
BR0316027A (en) Botulinum toxin formulations for oral administration
AR047841A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE-INFLAMMATORY DISORDERS
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
EA200702522A1 (en) SYSTEM OF DELIVERY OF MEDICINES IN THE CAVITY OF THE MOUTH AND METHODS OF ITS APPLICATION
AR057946A1 (en) FORMULATION OF SUSTAINED RELEASE ZONISAMIDE
ECSP045029A (en) VALDECOXIB COMPOSITIONS OF INTRAORAL DISGREGATION
SG152257A1 (en) Topical preparation containing ambroxol
IL201479A (en) Use of tapentadol for the manufacture of a medicament for the treatment of pain
CY1112738T1 (en) A COMBINED COMPOSITION CONTAINING Ibuprofen And Paracetamol
MX2010002498A (en) Methods of treating or preventing respiratory tract infection comprising administering cholecalciferol.
BRPI0513186A (en) medicinal composition for oral administration
ECSP099556A (en) NEW METHODS
BRPI0515070B8 (en) butylphthalide self-emulsifying drug delivery system and process for preparing butylphthalide self-emulsifying drug delivery system
MXPA06011467A (en) Active substance combination comprising a carbinol combined to at least an nsaid.
BR0208421A (en) Pharmaceutical formulation for mucosal administration to a patient, daily pharmaceutical dose, solid dispersion, use of pvp in solid dispersion with 4'-cyano-alpha ', alpha', alpha'-trifluoro-3- (4-fluoro phenylsulfonyl) - 2-hydroxy-2-methylpropiono-m-toluidide, and methods for increasing storage stability, bioavailability of the drug and for reducing the variation in plasma concentrations of 4'-cyano-alpha ', alpha', alpha ' , -trifluoro-3- (4-fluorophenylsulfonyl) -2-hydroxy-2-methylpropion-m-toluidide among patients
BRPI0411413A (en) enteric coating compositions of a natural product and lectin-containing enteric coated microcapsules
AR048318A1 (en) ORAL MATRIX FORMULATIONS THAT INCLUDE LICARBAZEPINA
ECSP045493A (en) NEW PHARMACEUTICAL COMPOSITIONS CONTAINING FLIBANSERINE POLYMORPH A
MXPA05012358A (en) Pharmaceutical combination comprising modafinil and another drug.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2143 DE 31/01/2012.